The 2023 Trends Shaping the Health Economy Report offers insight into 10 data-driven secular trends that are either intensifying or emerging, revealing the importance of delivering value for money.
With more than 100 data stories supporting the highlighted trends, this report synthesizes seemingly different data to provide greater context for every stakeholder – from providers and payers to life sciences and new entrants.
I hope this third edition of the annual Trends Shaping the Health Economy Report will cause you to reflect on the future of the U.S. health economy and think critically about what each trend means for your organization.
How will you deliver value for money to the individuals you serve?
Unlock Premium Insights with Compass+
Want to learn more about what the 10 secular trends impacting all health economy stakeholders mean for your organization?
Upgrade to Compass+ for a deeper dive into the trends that matter most with a premium subscriber-only version of the 2023 Health Economy Trends Report, which includes additional analyses, market-specific trends, ongoing tracking throughout the year and more.
An in-person executive leadership session for your team which will include a more detailed presentation and discussion of what the trends mean for your organization and specific markets
Interactive data dashboards to track industry trends all year
Library with pre-formatted slides across a variety of data trends to inform your internal presentations
Prescriptions for Ozempic and similar drugs soar past 9 million
Health-care providers wrote more than 9 million prescriptions for Ozempic and similar drugs in the final three months of 2022, according to a new analysis of medications that have become highly sought-after for their weight-loss effects.
These 15 metro areas saw biggest jumps in Ozempic use. They might not be where you expect.
A diabetes medication in short supply for the last two years often was prescribed to people who didn't have the disease, and prescribing rates varied dramatically across the country, new data shows.
Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients
As prescriptions for Ozempic soar, the drug and others like it are still reaching only a fraction of the population who could benefit from taking them — and the limited supply is disproportionately reaching White patients.